X0306 4 2018-02-21 0 0001446847 IRONWOOD PHARMACEUTICALS INC IRWD 0001546358 Consylman Gina C/O IRONWOOD PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Financial Officer Class A Common Stock 2018-02-21 4 S 0 376 14.66 D 59125 D Class A Common Stock 2018-02-21 4 S 0 1298 14.66 D 57827 D Class A Common Stock 2018-02-21 4 S 0 1920 14.66 D 55907 D Class A Common Stock 2018-02-21 4 A 0 30000 0.00 A 85907 D Employee Stock Option(Right to Buy) 14.55 2018-02-21 4 A 0 60000 0.00 A 2028-02-21 Class A Common Stock 60000 60000 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. /s/ Conor Kilroy, Attorney-in-Fact 2018-02-22